Search This Blog

Monday, January 13, 2025

QuidelOrtho prelims in line with views

 Fourth Quarter 2024 Preliminary Unaudited Revenues

The Company expects total reported revenues for the fourth quarter of 2024 to be in the range of approximately $702 million to $707 million, which would be in line with its previously announced 2024 financial guidance, including Labs revenue which is also in line with expectations. Expected fourth quarter 2024 total reported revenues include:

  • Non-respiratory reported revenue in the range of approximately $561 million to $563 million
  • Respiratory reported revenue in the range of approximately $141 million to $143 million1

“We closed the year on a positive note and expect to deliver top-line results above the mid-point of our 2024 financial guidance. Fiscal 2024 was an important year for our Company; we focused our team on our highest growth and profit opportunities, realigned our leadership team, and improved our cost structure by executing on significant cost-savings initiatives. We look forward to leveraging the results of these efforts as we move into fiscal 2025,” said Brian J. Blaser, President and Chief Executive Officer, QuidelOrtho.

The preliminary unaudited revenues described herein are based on management’s initial analysis for the fourth quarter ended December 29, 2024 and are subject to adjustments based on the Company’s completion of its year-end financial close process.

Conference Call Information

The Company expects to report its financial results for its fourth quarter and full year 2024 after the market closes on Wednesday, February 12, 2025.

Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at https://ir.quidelortho.com/. Presentation materials will also be posted to the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at the time of the call. Those unable to access the webcast may join the call via phone by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) and entering Conference ID number 356254.

A replay of the conference call will be available shortly after the event on the “Investor Relations” page of the Company’s website under the “Events & Presentations” section.

https://www.businesswire.com/news/home/20250113577245/en/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.